New Biomarkers of Chronic Hepatitis B.


Journal

Gut and liver
ISSN: 2005-1212
Titre abrégé: Gut Liver
Pays: Korea (South)
ID NLM: 101316452

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 20 09 2018
accepted: 12 11 2018
pubmed: 29 3 2019
medline: 24 4 2020
entrez: 29 3 2019
Statut: ppublish

Résumé

Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis B core-related antigen (HBcrAg) is a novel serum composite viral protein whose performance has been proven to be superior to that of existing viral markers. It showed good correlation with intrahepatic covalently closed-circular DNA. Its profile differs drastically in patients in different disease phases, and the level declines with antiviral therapies. HBcrAg may be helpful for predicting hepatocellular carcinoma development and hepatitis B virus (HBV) reactivation in immunosuppressed patients. Another emerging measurable serum marker, HBV RNA, exists in the form of pregenomic RNA-containing virions. Its profile differs between patients in different disease phases in a similar manner to that of HBcrAg. HBV RNA is present in serum at lower levels than HBV DNA in treatment-naïve patients by 1-2 logs. In contrast, its level is higher than HBV DNA in patients receiving nucleos(t)ide analogues (NAs). A significant decline in serum RNA was observed in patients receiving novel antiviral therapies, including core protein allosteric modulators and RIG-1/NOD2 agonists. Both HBcrAg and HBV RNA may be helpful for predicting off-therapy sustained virological control in patients who stop long-term NA treatment.

Identifiants

pubmed: 30919601
pii: gnl18425
doi: 10.5009/gnl18425
pmc: PMC6860035
doi:

Substances chimiques

Biomarkers 0
Hepatitis B Core Antigens 0
RNA, Viral 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-595

Références

Clin Cancer Res. 2001 Jul;7(7):2005-15
pubmed: 11448918
Gastroenterology. 2008 Oct;135(4):1192-9
pubmed: 18722377
Liver Int. 2017 Jul;37(7):995-1001
pubmed: 27992681
J Viral Hepat. 2018 Sep;25(9):1038-1047
pubmed: 29633430
Clin Microbiol Infect. 2014 Nov;20(11):1173-80
pubmed: 24975365
J Clin Microbiol. 2007 Dec;45(12):3942-7
pubmed: 17942661
J Hepatol. 2016 Apr;64(1 Suppl):S117-S131
pubmed: 27084032
Nat Rev Dis Primers. 2018 Jun 07;4:18035
pubmed: 29877316
Clin Mol Hepatol. 2016 Sep;22(3):382-389
pubmed: 27729633
Hepatology. 2018 Dec;68(6):2106-2117
pubmed: 29734472
Hepatology. 2018 Aug;68(2):462-472
pubmed: 29534307
J Clin Microbiol. 2002 Feb;40(2):439-45
pubmed: 11825954
J Gastroenterol. 2013 Oct;48(10):1188-204
pubmed: 23397114
J Biol Chem. 2005 Jun 10;280(23):21713-9
pubmed: 15814524
Clin Transl Gastroenterol. 2017 Oct 26;8(10):e125
pubmed: 29072673
Aliment Pharmacol Ther. 2018 Jan;47(1):43-54
pubmed: 29035003
J Viral Hepat. 2017 Aug;24(8):654-661
pubmed: 28185363
J Hepatol. 2016 Jul;65(1):48-56
pubmed: 27034253
J Hepatol. 2017 Feb;66(2):462-463
pubmed: 27826054
Ann Intern Med. 2007 Jul 3;147(1):58-61
pubmed: 17606962
J Gastroenterol. 2006 Aug;41(8):785-90
pubmed: 16988768
J Virol. 1996 Jul;70(7):4269-74
pubmed: 8676448
J Hepatol. 2017 Feb;66(2):275-281
pubmed: 27639844
Antivir Ther. 2015;20(4):369-75
pubmed: 24739420
J Hepatol. 2005 Mar;42(3):302-8
pubmed: 15710212
Am J Gastroenterol. 2016 Dec;111(12):1788-1795
pubmed: 27644733
J Gastroenterol Hepatol. 2005 Nov;20(11):1726-30
pubmed: 16246193
Hepatology. 2015 Jan;61(1):66-76
pubmed: 25132147
J Hepatol. 2016 Oct;65(4):700-710
pubmed: 27245431
J Viral Hepat. 2003 Jul;10(4):324-30
pubmed: 12823601
J Gastroenterol. 2016 Aug;51(8):830-9
pubmed: 26687058
J Infect Dis. 2016 Jan 15;213(2):224-32
pubmed: 26216905
J Virol. 2003 Feb;77(3):2287-94
pubmed: 12525667
Immunity. 2015 Jan 20;42(1):123-32
pubmed: 25557055
J Clin Microbiol. 2017 Oct;55(10):2972-2982
pubmed: 28747369
Gut. 2014 Aug;63(8):1325-32
pubmed: 24162593
Hepatology. 1998 Jun;27(6):1736-42
pubmed: 9620351
Gastroenterology. 2010 Aug;139(2):474-82
pubmed: 20434450
Hepatology. 2007 May;45(5):1179-86
pubmed: 17465002
Clin Microbiol Infect. 2015 Jun;21(6):606.e1-10
pubmed: 25700889
Chin Med J (Engl). 2016 20th Sep;129(18):2212-9
pubmed: 27625094
Hepatol Int. 2012 Mar 13;7(1):98-105
pubmed: 24014110
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Med Virol. 2009 Jan;81(1):27-33
pubmed: 19031469
J Gastroenterol. 2013 Jun;48(6):777-8
pubmed: 23543314

Auteurs

Lung-Yi Mak (LY)

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.

Wai-Kay Seto (WK)

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

James Fung (J)

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.

Man-Fung Yuen (MF)

Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH